	US 12,263,190 B2
	Methods and combinations for treatment and T cell modulation
Jens Hasskarl, Boudry (CH); Stanley R. Frankel, Summit, NJ (US); Michael Ports, Seattle, WA (US); Michael Pourdehnad, Summit, NJ (US); Heidi Jessup, Seattle, WA (US); Yue Jiang, Seattle, WA (US); Jim Shi Xiang Qin, Seattle, WA (US); Neha Soni, Seattle, WA (US); and Melissa Works, Seattle, WA (US)
Assigned to Juno Therapeutics, Inc., Seattle, WA (US)
Appl. No. 17/292,363
Filed by Juno Therapeutics, Inc., Seattle, WA (US)
PCT Filed Nov. 7, 2019, PCT No. PCT/US2019/060367 § 371(c)(1), (2) Date May 7, 2021, PCT Pub. No. WO2020/097403, PCT Pub. Date May 14, 2020.
Claims priority of provisional application 62/826,928, filed on Mar. 29, 2019.
Claims priority of provisional application 62/757,755, filed on Nov. 8, 2018.
Prior Publication US 2022/0008477 A1, Jan. 13, 2022
Int. Cl. A61K 35/28 (2015.01); A61K 39/00 (2006.01); A61P 35/02 (2006.01); A61P 43/00 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01)

CPC A61K 35/28 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464412 (2023.05); A61K 39/464417 (2023.05); A61P 35/02 (2018.01); A61P 43/00 (2018.01); C07K 16/2809 (2013.01); C07K 16/2866 (2013.01); C07K 16/2896 (2013.01); C12N 5/0636 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05)]

33 Claims

1. A method of treatment, comprising:

(a) administering a T cell therapy to a subject having a cancer, said T cell therapy comprising a dose of T cells expressing a recombinant antigen receptor that binds to a target antigen; and

(b) administering to the subject an immunomodulatory compound, wherein the compound is(S) -3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.